Adverse event totals12

The totals the trial posted for each group.

1 to 12 of 12

Total	Group	Affected	At risk
Total, all-cause mortality	Placebo
Total, all-cause mortality	Brodalumab 210 mg
Total, all-cause mortality	Brodalumab 350 mg
Total, all-cause mortality	Brodalumab 700 mg
Total, other adverse events	Placebo	20	32
Total, other adverse events	Brodalumab 210 mg	21	31
Total, other adverse events	Brodalumab 350 mg	23	32
Total, other adverse events	Brodalumab 700 mg	20	33
Total, serious adverse events	Placebo	2	32
Total, serious adverse events	Brodalumab 210 mg	3	31
Total, serious adverse events	Brodalumab 350 mg	8	32
Total, serious adverse events	Brodalumab 700 mg	9	33

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01150890/event-totals